Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino Sells 4,000 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $5.38, for a total value of $21,520.00. Following the sale, the director now owns 64,334 shares in the company, valued at approximately $346,116.92. This trade represents a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mark Alvino also recently made the following trade(s):

• On Tuesday, January 21st, Mark Alvino sold 4,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.10, for a total value of $20,400.00.

Abeona Therapeutics Stock Performance

ABEO stock opened at $5.54 on Friday. Abeona Therapeutics Inc has a twelve month low of $3.05 and a twelve month high of $9.01. The firm has a market cap of $240.82 million, a price-to-earnings ratio of -2.06 and a beta of 1.46. The business’s fifty day simple moving average is $5.73 and its two-hundred day simple moving average is $5.72. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Wall Street Analyst Weigh In

Several research analysts have commented on ABEO shares. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ABEO. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the 3rd quarter valued at about $84,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics during the third quarter worth approximately $151,000. XTX Topco Ltd bought a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $160,000. JPMorgan Chase & Co. boosted its holdings in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 28,606 shares during the period. Finally, GSA Capital Partners LLP grew its stake in Abeona Therapeutics by 54.3% in the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 33,831 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.